FDA Staff Weighs 'Alternative' Data on Retinoid for Rare Bone Disorder

(MedPage Today) -- Credit: Joh-co Study design, problematic statistical analyses, and risk management appeared to blunt the enthusiasm of FDA staff reviewing the investigational agent palovarotene for fibrodysplasia ossificans progressiva...
Source: MedPage Today Public Health - Category: American Health Source Type: news